Catalyst Pharmaceuticals (CPRX) Rating Lowered to Buy at BidaskClub
Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.
CPRX has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. SunTrust Banks reaffirmed a “buy” rating and set a $5.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.25.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.17 on Thursday, hitting $4.00. 1,321,413 shares of the stock were exchanged, compared to its average volume of 2,226,653. Catalyst Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.51.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.